Leslie Lundt, MD

Onset and Resolution of Key Adverse Events in Valbenazine-Treated Patients with Tardive Dyskinesia: Pooled Post Hoc Analyses from Two Long-Term Clinical Trials

Background: Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotics and other dopamine receptor blocking a...

Jean-Pierre Lindenmayer , MD;

Stephen Marder , MD;

Tara Carmack , MS;

Angel Angelov , MD;

Chirag B. Shah , PharmD, MD;

Leslie Lundt , MD;

10/08/2020

Early Response With Valbenazine and Long-Term Symptom Reduction in Patients With Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study

Background: Valbenazine is approved for the treatment of tardive dyskinesia (TD), a persistent and disabling movement disorder associated with prolonged antipsychotic exposure. Data from ...

Khodayar Farahmand , PharmD;

Jean-Pierre Lindenmayer , MD;

Stephen Marder , MD;

Stewart Factor , DO;

Leslie Lundt , MD;

Stanley Caroff , MD;

11/22/2019

Long-Term Treatment With Valbenazine 40 mg Once-Daily in Adults With Tardive Dyskinesia

Background: Valbenazine, a novel and highly selective VMAT2 inhibitor, is approved for the treatment of TD in adults. Data from two long-term studies (KINECT 3 [K3], KINECT 4 [K4]) and a ...

Carlos Singer , MD;

Leslie Lundt , MD;

Craig Chepke , MD, DFAPA;

Khodayar Farahmand , PharmD;

Cynthia Comella , MD;

11/22/2019

Effects of Concomitant Medication Use on Tardive Dyskinesia Outcomes in Long-Term Valbenazine Trials

Background: Patients with tardive dyskinesia (TD) often take multiple concomitant medications for psychiatric comorbidities. Data from long-term valbenazine trials were analyzed to evalua...

Richard Josiassen , PhD;

Leslie Lundt , MD;

Andrew J. Cutler , MD;

Khodayar Farahmand , PharmD;

John Kane , MD;

Joshua Burke , MS;

Scott Siegert , PharmD;

03/01/2019

Effects of Long-Term Valbenazine on Psychiatric Status in Patients With Tardive Dyskinesia and a Primary Mood Disorder

Objective: In two long-term phase 3 studies, sustained TD improvements were observed in participants who received once-daily treatment with valbenazine (40 or 80 mg). Data from these stud...

Joshua Burke , MS;

Scott Siegert , PharmD;

Gary Remington , MD, PhD;

Rachel Weber , PhD;

Leslie Lundt , MD;

Khodayar Farahmand , PharmD;

Christoph U. Correll , MD;

Roger McIntyre , MD, FRCPC;

03/01/2019

Clinician-Reported Patient Awareness of Symptoms and Severity of Tardive Dyskinesia in Patients Prescribed VMAT2 Inhibitors

Background: Vesicular monoamine transporter 2 (VMAT2) inhibitors including valbenazine are first-line therapies for tardive dyskinesia (TD), a persistent movement disorder associated with...

Leslie Lundt , MD;

Chuck Yonan , PharmD;

Rahul Dhanda , PhD;

Jonathan Meyer , MD;

Betsy Benning ;

Ericha Franey , PhD;

Edward Goldberg , MD;

10/18/2020

Concerns from Community Mental Health Center (CMHC) Patients Regarding Drug-Induced Movement Disorders: Impact on Functioning and Treatment Beliefs

Background: Drug-induced movement disorders (DIMDs) may occur in patients treated with antipsychotics. The CommonGround Program supports the recovery and healing of psychiatric outpatient...

Allison Stiles , MA, LPC;

Ericha Franey , PhD;

Edward Goldberg , MD;

Leslie Lundt , MD;

Chuck Yonan , PharmD;

Rahul Dhanda , PhD;

10/08/2020

Understanding the evolving continuing medical education needs of physicians managing patients with TD

This study sought to understand the evolving continuing medical education (CME) needs of physicians managing patients with tardive dyskinesia (TD). A case-based survey was developed, and ...

Sylvie Stacy , MD, MPH;

Shereta Wiley , MPH;

Khodayar Farahmand , PharmD;

Wendy Cerenzia , MS;

Chirag B. Shah , PharmD, MD;

Leslie Lundt , MD;

10/08/2020